MENCARELLI, Andrea
 Distribuzione geografica
Continente #
NA - Nord America 2.438
EU - Europa 1.721
AS - Asia 750
SA - Sud America 47
Continente sconosciuto - Info sul continente non disponibili 5
AF - Africa 1
Totale 4.962
Nazione #
US - Stati Uniti d'America 2.427
UA - Ucraina 412
IE - Irlanda 400
SG - Singapore 282
SE - Svezia 214
IT - Italia 212
VN - Vietnam 144
DE - Germania 122
HK - Hong Kong 121
CN - Cina 118
FI - Finlandia 117
RU - Federazione Russa 85
FR - Francia 49
TR - Turchia 48
BR - Brasile 40
GB - Regno Unito 27
KR - Corea 22
RO - Romania 19
CH - Svizzera 18
CZ - Repubblica Ceca 15
CA - Canada 9
BE - Belgio 8
NL - Olanda 6
EU - Europa 5
GR - Grecia 5
UZ - Uzbekistan 5
AT - Austria 4
LB - Libano 4
PL - Polonia 4
EC - Ecuador 3
CO - Colombia 2
DK - Danimarca 2
MX - Messico 2
AE - Emirati Arabi Uniti 1
CL - Cile 1
DZ - Algeria 1
HU - Ungheria 1
IQ - Iraq 1
JO - Giordania 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LT - Lituania 1
NP - Nepal 1
PY - Paraguay 1
Totale 4.962
Città #
Chandler 481
Dublin 400
San Mateo 224
Singapore 217
Jacksonville 190
Wilmington 149
Dong Ket 144
Boardman 136
Hong Kong 121
Altamura 119
Santa Clara 110
Medford 100
Princeton 100
Lawrence 83
Andover 69
Ann Arbor 66
Perugia 58
Beijing 47
Izmir 46
Ashburn 44
Des Moines 42
Falls Church 35
Saint Petersburg 28
Helsinki 19
Norwalk 17
New York 14
San Paolo di Civitate 14
Los Angeles 13
Timisoara 13
Seoul 11
Woodbridge 11
Olomouc 9
Brussels 8
Ottawa 8
Moscow 7
Shanghai 7
Bucharest 6
Dearborn 6
Munich 6
Auburn Hills 5
Houston 5
São Paulo 5
Dallas 4
Redwood City 4
Den Haag 3
Lausanne 3
Phoenix 3
Rovato 3
Americana 2
Curitiba 2
Frankfurt Am Main 2
Guangzhou 2
Redmond 2
Simi Valley 2
Al Ain City 1
Alameda 1
Almaty 1
Amman 1
Antakya 1
Aparecida de Goiânia 1
Atatürk 1
Atlanta 1
Baghdad 1
Belo Horizonte 1
Benxi 1
Birigui 1
Bishkek 1
Budapest 1
Cangzhou 1
Capelinha 1
Cartagena 1
Cascavel 1
Caxias do Sul 1
Centro 1
Changsha 1
Chongqing 1
Clifton 1
Contagem 1
Copenhagen 1
Deruta 1
Dongguan 1
Edinburgh 1
Falkenstein 1
Fuzhou 1
Guaratinga 1
Guayaquil 1
Hanover 1
Ipojuca 1
Itaboraí 1
Joinville 1
Jundiaí 1
Kiev 1
Leme 1
London 1
Ludwigshafen 1
Matozinhos 1
Mexico City 1
Miami 1
Mirassol 1
Moju 1
Totale 3.271
Nome #
Recombinant galectin-1 prevents experimental colitis in mice via T cell apoptosis. 159
GITR modulates innate and adaptive mucosal immunity during the development of experimental colitis in mice 96
An NO-derivative of acetaminophen, NCX-701, spares the liver by inhibiting Fas-dependent apoptosis 95
Activation of the farnesoid-X receptor protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs in mice. 90
Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice. 89
Activation of the bile acid receptor GPBAR1 protects against gastrointestinal injury caused by non-steroidal anti-inflammatory drugs and aspirin in mice. 88
An NO derivative of ursodeoxycholic acid protects against Fas-mediated liver injury by inhibiting caspase activity 87
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation. 81
A nitro-arginine derivative of trimebutine (NO2-Arg-Trim) attenuates pain induced by colorectal distension in conscious rats. 75
Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. 75
Antiatherosclerotic effect of farnesoid X receptor. 73
Reciprocal regulation of the bile acid-activated receptor FXR and the interferon-gamma-STAT-1 pathway in macrophages. 70
Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition 70
5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. 69
An essential role of Farnesoid X-Receptor in regulating intestinal fibrosis in murine model of chronic colitis 69
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension 67
Activation of FXR Improves Myocardial Fatty Acid Metabolism in a Rodent Model of Liver Steatosis 66
Cyclooxygenase-2-derived lipoxin A4 increases gastric resistance to aspirin-induced damage. 65
Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. 65
a Farnesoid-X-Receptor (FXR)-Glucocorticoid Receptor (GR) Cascade Regulates Intestinal Innate Immunity in Response to FXR Activation 64
A beta-oxidation-resistant lipoxin A(4) analog treats hapten-induced colitis by attenuating inflammation and immune dysfunction 64
Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatorybowel diseases and arthritis 59
3-oxa-lipoxin A4 analog treats colitis induced by Dss by attenuating inflammation and immunity. 59
Cardiac safety and antitumoral activity of a new nitric oxide derivative of pegylated epirubicin in mice. 58
Ritonavir-induced lipoatrophy and dyslipidaemia is reversed by the anti-inflammatory drug leflunomide in a PPAR-γ-dependent manner. 58
Counter-regulatory role of bile acid activated receptors in immunity andinflammation. 58
4-Methylenesterols from Theonella swinhoei sponge are natural pregnane-X-receptor agonists and farnesoid-X-receptor antagonists that modulate innate immunity. 58
Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammation 58
The bile acid sensor FXR protects against dyslipidemia and aortic plaques development induced by the HIV protease inhibitor ritonavir in mice. 57
Farnesoid X receptor suppresses constitutive androstane receptoractivity at the multidrug resistance protein-4 promoter. 57
The HIV Matrix Protein p17 subverts Nuclear Receptors Expression and induces a STAT1-Dependent Proinflammatory Phenotype in Monocytes 57
Nitric oxide protects againist HIV gp 120 endothelial injury. 57
FXR mediates a chromatin looping in the GR promoter thus promoting the resolution of colitis in rodents. 57
The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis. 56
Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA 55
Proteinase activated receptor (PAR)-2 agonistic peptide protects from Th-1 mediated liver injury in mice. 55
NCX-1000, an NO derivative of UDCA, releases NO and protects against portal hypertension by inhibiting hepatic stellate cell contraction. 55
Role of the FXR in Regulating Bile Acid Homeostasis and Relevance for Human Diseases 54
The plant sterol guggulsterone attenuates inflammation and immune dysfunction in murine models of inflammatory bowel disease. 53
Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. 53
The third gas: H2S regulates perfusion pressure in both theisolated and perfused normal rat liver and in cirrhosis. 53
Proteinase activated receptor (PAR)-2 protects against colitis in mice. Evidence for direct modulation of lamina propria T lymphocytes. 53
A hydrogen-sulfide releasing derivative of mesalamine exhibits markedly enhanced anti-inflammatory effects in experimental colitis 53
Discovery that theonellasterol a marine sponge sterol is a highly selective FXR antagonist that protects against liver injury in cholestasis. 53
Evidence that hydrogen sulfide exerts antinociceptive effects in the gastrointestinal tract by activating KATP channels. 52
Relative contribution of acetylated cyclo-oxygenase (COX)-2 and 5-lipooxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. 52
Inhibition of NF-κB by a PXR-dependent pathwaymediates counter-regulatory activities of rifaximin on innate immunity inintestinal epithelial cells. 51
Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons 51
IL-1 beta converting enzyme is a target for nitric oxide-releasing aspirin: new insights in the antiinflammatory mechanism of nitric oxide-releasing nonsteroidal antiinflammatory drugs. 50
COX-2 selective inhibitors cause gastric damage in aspirin treated rats. Protective effect of nitroaspirin (NCX-4016). 49
The nuclear receptor FXR regulates hepatic transport and metabolism of glutamine and glutamate 48
Critical role of toll-like receptors in modulating GM-CSF activity in rodent models of colitis 48
Gene Expression Changes Induced by HIPEC in a Murine Model of Gastric Cancer 47
The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. 46
Epigenetic modulation by methionine deficiency attenuates the potential for gastric cancer cell dissemination. 46
Nitric oxide modulates proapoptotic and antiapoptotic properties of chemotherapy agents: the case of NO-pegylated epirubicin. 45
SHP-dependent and -independent induction of peroxisomeproliferator-activated receptor-γ by the bile acid sensor farnesoid X receptorcounter-regulates the pro-inflammatory phenotype of liver myofibroblasts. 45
Targetting farnesoid-X-receptor: from medicinal chemistry to disease treatment. 45
VLA-1 immunoneutralization protects against colon damage in a mouse model of colitis 44
FXR Activation Reverses Insulin Resistance and Protects Against NASH Development 44
NCX-999, a NO-releasing derivative of UDCA, modulates hepatic stellate cells and reduces vasomotor response to nor-epinefrine in intact rats 44
In vivo administration of ritonavir worsens intestinal damage caused by cyclooxygease inhibitors. 44
CCR5 Antagonism by Maraviroc Reduces the Potential for Gastric Cancer Cell Dissemination. 43
Hydrogen sulphide induces micro opioid receptor-dependent analgesia in a rodent model of visceral pain. 42
The methionine connection: homocysteine and hydrogen sulfide exert opposite effects on hepatic microcirculation in rats. 42
FXR an emerging therapeutic target for the treatment of atherosclerosis. 42
The bile acid receptor FXR is a modulator of intestinal innate immunity. 42
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. 41
Instruction of Intestinal Microbiota by VSL#3 Reverses NASH and Accelerated Atherosclerosis Caused by Intestinal Inflammation in ApoE(-/-) Mice 41
Farnesoid-X-receptor (FXR) ligands induce a small heterodimer partner (SHP)-dependent upregulation of PPAR-gamma in hepatic stellate cells and in rat model of liver fibrosis. 41
A Novel Source of Intestinal Damage: The HIV Protease Inhibitor Ritonavir Worsens Damage Caused by COX Inhibitors 40
Inhibition of hydrogen sulfide generation contributes to gastric injury caused byanti-inflammatory nonsteroidal drugs. 39
Different sensitivity of lamina propria T-cell subsets to nitric oxide-induced apoptosis explains immunomodulatory activity of a nitric oxidereleasing derivative of mesalamine in rodent colitis. 38
The nuclear receptor SHP (small heterodimer partner) mediates inhibitory effects of farnesoid-X-receptor (FXR) on hepatic stellate cells and protects against liver fibrosis in rodents. 38
H2S Induces Analgesia Is Mediated In Vivo Activation of mu Opioid Receptor and PI3K/AKT Pathway Activation 38
Total synthesis and pharmacological characterization of solomonsterol A, a potent marine pregnane-X-receptor agonist endowed with anti-inflammatory activity. 37
Impaired calcineurin signaling in myeloid cells results in downregulation of pentraxin-3 and increased susceptibility to aspergillosis 37
Protective effects of granulocyte macrophage colony stimulating factor (gm-Csf) in Hapten-induced colitis 36
Co-administration of nitric oxide-aspirin (NCX-4016) andaspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans. 35
Role of Maraviroc in a dyslipidemic murine model of atherosclerosis RTV-induced 35
The CCR5 Antagonist Maraviroc Reduces the Potential for Gastric Cancer Dissemination in Rodent Models of Peritoneal Metastasis 35
Essential Role of DNAX Adaptor Protein 12 (DAP12) and Spleen Tyrosine Kinase (Syk) in Inflammation-Driven Immune Dysfunction in Rodent Model of Colitis 34
Solomonsterol A, a marine pregnane-X-receptor agonist, attenuates inflammation and immune dysfunction in a mouse model of arthritis. 34
Molecular Determinants of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in a Model of Peritoneal Gastric Cancer Carcinogenesis 33
‘The Farnesoid X Receptor Promotes Adipocyte Differentiationd regulates adipose cell function in vivo’ 32
The Bile Acid Receptor TGR5 Maintains Gastrointestinal Homeostasis and Its Activation Rescues From Gastrointestinal Injury Caused by ASA and NSAIDs 31
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. 31
The bile acid sensor FXR is required for immune-regulatory activities of TLR-9 in intestinal inflammation 31
Heat shock proteins as key biological targets of the marine natural cyclopeptide perthamide 30
The bile acid sensor FXR regulates insulin transcription and secretion. 30
Enhanced anti-inflammatory activity of hydrogen sulfide releasing derivative of mesalamine in rodent models of colitis, involves direct inhibition of Nf-kappa B 29
Celecoxib exacerbates gastrointestinal damage induced by aspirin but not by NO-aspirin (NCX-4016): A randomised, parallel group, blind-observer endoscopic study. Evidence for a protective role of NO in the gastrointestinal mucosa 29
Inhibition of NF-kB by a PXR-Dependent Pathway Mediates Counter-regulatory Activities of Rifaximin on Innate Immunity in Intestinal Epithelial Cells 29
VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation. 28
Modification of Intestinal Microbiota by VSL#3 Protects Against Development of Pain in the Neonatal Maternal Separation Model. a Whole Genome Array Investigation 28
The Farnesoid X Receptor Promotes Adipocyte Differentiation and Regulates Adipose Cell Function in Vivo 27
FXR Activation Corrects Immune-Dysfunction and Attenuates Inflammation in a Rodent Model of Hepatitis 26
The Nuclear Receptor SHP Mediates Inhibition of Hepatic Stellate Cells by FXR and Protects Against Liver Fibrosis 26
Gastrointestinal safety and anti-inflammatory activity of HCT-1026, NO-releasing flurbiprofen, in healthy humans volunteers 25
Plakilactones from the Marine Sponge Plakinastrella mamillaris. Discovery of a New Class of Marine Ligands of Peroxisome Proliferator-Activated Receptor gamma 25
Totale 5.114
Categoria #
all - tutte 23.991
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.991


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020159 0 0 0 0 0 0 0 12 86 38 6 17
2020/2021884 3 78 41 91 253 37 50 8 74 20 70 159
2021/2022877 15 152 9 32 32 120 5 274 4 8 75 151
2022/20231.563 116 295 8 154 114 173 1 84 556 0 50 12
2023/2024509 35 67 36 4 4 4 109 36 32 17 104 61
2024/2025531 10 117 53 46 212 49 28 16 0 0 0 0
Totale 5.114